Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SBC Medical Group Holdings ( (SBC) ) has provided an update.
On March 27, 2026, SBC Medical Group Holdings reported fourth-quarter and full-year 2025 results showing a business in transition, with revenue contracting but profitability improving as earlier restructuring and franchise fee changes worked through the model. Fourth-quarter 2025 revenue fell 11% year on year to $40 million while net income jumped 117% to $14 million and EPS more than doubled to $0.14, even as EBITDA declined 35% and the EBITDA margin narrowed to 34% amid margin normalization and prior period adjustments.
For full-year 2025, revenue slipped 15% to $174 million but net income rose 9% to $51 million, EPS edged up 4% to $0.50 and net income margin expanded from 23% to 29%, helped by the absence of prior IPO-related stock compensation and impairments. Operationally, the group ended 2025 with 283 franchise locations, 6.6 million customers over the last 12 months, an improved average revenue per customer of $316 in the fourth quarter, and a 72% repeat customer rate, underscoring resilient demand even as SBC pivots toward a multi-brand dermatology strategy, broader non-aesthetic healthcare offerings and stronger international foundations.
The company also posted a new “Group Business” investor presentation to its website on March 27, 2026 and highlighted that online disclosures may contain material information, reinforcing digital channels as a core element of its investor communications strategy. In parallel with the earnings report, SBC announced updates to its business strategy and capital policy, signaling a shift from restructuring to re-accelerating sustainable top-line growth, and scheduled a same-day conference call to brief investors on the 2025 performance and the 2026 strategic agenda.
The most recent analyst rating on (SBC) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SBC Medical Group Holdings stock, see the SBC Stock Forecast page.
Spark’s Take on SBC Stock
According to Spark, TipRanks’ AI Analyst, SBC is a Outperform.
The score is driven by strong profitability and a low-leverage balance sheet, supported by constructive technical momentum. The main constraint is operational/cash-flow risk (negative operating cash flow and declining TTM revenue growth), while valuation appears reasonable (P/E ~10.3) and recent corporate actions are broadly positive.
To see Spark’s full report on SBC stock, click here.
More about SBC Medical Group Holdings
SBC Medical Group Holdings is a Nasdaq-listed management services organization that operates a broad portfolio of franchise clinic brands across advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia care and ophthalmology. The group is expanding internationally, with a strategic focus on the United States and Asia and on medical tourism, and was added to the Russell 3000 Index in June 2025.
The company positions itself as a provider of safe, high-quality medical services while leveraging medical innovation to build its global reputation for trusted care. It supports franchisees across multiple brands, including SBC, Rize Clinic, Gorilla Clinic, AHH Clinic and JUN CLINIC, and uses its website as a key channel for disseminating investor information and corporate disclosures.
Average Trading Volume: 30,191
Technical Sentiment Signal: Strong Sell
Current Market Cap: $389.8M
See more insights into SBC stock on TipRanks’ Stock Analysis page.